Annual CFI
-$86.83 M
-$81.51 M-1531.22%
31 December 2022
Summary:
Eagle Pharmaceuticals annual cash flow from investing activities is currently -$86.83 million, with the most recent change of -$81.51 million (-1531.22%) on 31 December 2022. During the last 3 years, it has fallen by -$68.58 million (-375.86%). EGRX annual CFI is now -3026.53% below its all-time high of $2.97 million, reached on 30 September 2012.EGRX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$6000.00
+$12.55 M+99.95%
30 June 2023
Summary:
Eagle Pharmaceuticals quarterly cash flow from investing activities is currently -$6000.00, with the most recent change of +$12.55 million (+99.95%) on 30 June 2023. EGRX quarterly CFI is now -100.01% below its all-time high of $64.93 million, reached on 30 September 2015.EGRX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$23.81 M
+$75.41 M+76.00%
30 June 2023
Summary:
Eagle Pharmaceuticals TTM cash flow from investing activities is currently -$23.81 million, with the most recent change of +$75.41 million (+76.00%) on 30 June 2023. EGRX TTM CFI is now -128.20% below its all-time high of $84.44 million, reached on 30 June 2016.EGRX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EGRX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -375.9% | -20.0% | -337.4% |
| 5 y5 years | -10000.0% | +98.0% | -3170.6% |
EGRX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1531.2% | at low | -20.0% | +100.0% | <-9999.0% | +76.0% |
| 5 y | 5 years | <-9999.0% | at low | -105.2% | +100.0% | <-9999.0% | +76.0% |
| alltime | all time | -3026.5% | at low | -100.0% | +100.0% | -128.2% | +76.0% |
Eagle Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$6000.00(-100.0%) | -$23.81 M(-76.0%) |
| Mar 2023 | - | -$12.56 M(>+9900.0%) | -$99.22 M(+14.3%) |
| Dec 2022 | -$86.83 M(+1531.2%) | -$9000.00(-99.9%) | -$86.83 M(-0.0%) |
| Sept 2022 | - | -$11.24 M(-85.1%) | -$86.87 M(+14.8%) |
| June 2022 | - | -$75.42 M(>+9900.0%) | -$75.64 M(>+9900.0%) |
| Mar 2022 | - | -$168.00 K(+242.9%) | -$107.00 K(-98.0%) |
| Dec 2021 | -$5.32 M(-70.8%) | -$49.00 K(+880.0%) | -$5.32 M(-2.2%) |
| Sept 2021 | - | -$5000.00(-104.3%) | -$5.44 M(-3.5%) |
| June 2021 | - | $115.00 K(-102.1%) | -$5.64 M(-0.3%) |
| Mar 2021 | - | -$5.38 M(+3067.1%) | -$5.66 M(-69.0%) |
| Dec 2020 | -$18.25 M(+2248.4%) | -$170.00 K(-15.4%) | -$18.25 M(+0.2%) |
| Sept 2020 | - | -$201.00 K(-309.4%) | -$18.21 M(-0.6%) |
| June 2020 | - | $96.00 K(-100.5%) | -$18.31 M(-1.4%) |
| Mar 2020 | - | -$17.97 M(>+9900.0%) | -$18.57 M(+2290.2%) |
| Dec 2019 | -$777.00 K(+484.2%) | -$130.00 K(-57.2%) | -$777.00 K(+6.7%) |
| Sept 2019 | - | -$304.00 K(+83.1%) | -$728.00 K(+59.3%) |
| June 2019 | - | -$166.00 K(-6.2%) | -$457.00 K(+57.0%) |
| Mar 2019 | - | -$177.00 K(+118.5%) | -$291.00 K(+118.8%) |
| Dec 2018 | -$133.00 K(-97.4%) | -$81.00 K(+145.5%) | -$133.00 K(-95.2%) |
| Sept 2018 | - | -$33.00 K(<-9900.0%) | -$2.78 M(-35.6%) |
| June 2018 | - | $0.00(-100.0%) | -$4.32 M(-4.6%) |
| Mar 2018 | - | -$19.00 K(-99.3%) | -$4.53 M(-12.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | -$5.19 M(-88.7%) | -$2.73 M(+73.7%) | -$5.19 M(-82.8%) |
| Sept 2017 | - | -$1.57 M(+655.8%) | -$30.07 M(-29.5%) |
| June 2017 | - | -$208.00 K(-69.2%) | -$42.68 M(+0.3%) |
| Mar 2017 | - | -$676.00 K(-97.6%) | -$42.57 M(-7.0%) |
| Dec 2016 | -$45.80 M(+2334.9%) | -$27.62 M(+94.8%) | -$45.80 M(-958.6%) |
| Sept 2016 | - | -$14.18 M(>+9900.0%) | $5.33 M(-93.7%) |
| June 2016 | - | -$100.00 K(-97.4%) | $84.44 M(+723.3%) |
| Mar 2016 | - | -$3.90 M(-116.6%) | $10.26 M(-645.2%) |
| Dec 2015 | -$1.88 M(-90.6%) | $23.52 M(-63.8%) | -$1.88 M(-65.2%) |
| Sept 2015 | - | $64.93 M(-187.4%) | -$5.41 M(-94.0%) |
| June 2015 | - | -$74.28 M(+363.1%) | -$90.34 M(+462.4%) |
| Mar 2015 | - | -$16.04 M(-180.3%) | -$16.06 M(>+9900.0%) |
| Dec 2014 | - | $19.99 M(-199.9%) | -$50.00 K(-99.8%) |
| Sept 2014 | -$20.05 M(-1473.9%) | -$20.01 M(>+9900.0%) | -$20.05 M(>+9900.0%) |
| June 2014 | - | -$4200.00(-84.8%) | -$49.10 K(-35.1%) |
| Mar 2014 | - | -$27.60 K(+294.3%) | -$75.60 K(+57.5%) |
| Dec 2013 | - | -$7000.00(-32.0%) | -$48.00 K(-103.3%) |
| Sept 2013 | $1.46 M(-50.8%) | -$10.30 K(-66.4%) | $1.46 M(-0.7%) |
| June 2013 | - | -$30.70 K(<-9900.0%) | $1.47 M(-2.0%) |
| Mar 2013 | - | $0.00(-100.0%) | $1.50 M(0.0%) |
| Dec 2012 | - | $1.50 M | $1.50 M |
| Sept 2012 | $2.97 M | - | - |
FAQ
- What is Eagle Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Eagle Pharmaceuticals?
What is Eagle Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of EGRX is -$86.83 M
What is the all time high annual CFI for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high annual cash flow from investing activities is $2.97 M
What is Eagle Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of EGRX is -$6000.00
What is the all time high quarterly CFI for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high quarterly cash flow from investing activities is $64.93 M
What is Eagle Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of EGRX is -$23.81 M
What is the all time high TTM CFI for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high TTM cash flow from investing activities is $84.44 M